Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, trametinib (Mekinist®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. |
||
|
||
Medicine details |
||
| Medicine name | trametinib (Mekinist®) | |
| Formulation | 0.5 mg film-coated tablet, 1.0 mg film-coated tablet, 2.0 mg film-coated tablet | |
| Reference number | 1011 | |
| Indication | For the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. |
|
| Company | Novartis Pharmaceuticals UK Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 28/01/2015 | |
| Date of issue | 29/01/2015 | |